Form 4: Centessa Pharmaceuticals Director, Arjun Goyal, Acquires Share Options
SEC Form 4 Filing
Director Arjun Goyal acquired 48,000 share options in Centessa Pharmaceuticals on June 25, 2024.
Summary
- Arjun Goyal, a director of Centessa Pharmaceuticals plc, acquired 48,000 share options on June 25, 2024.
- The exercise price of these options is $8.89.
- The options vest on the earlier of the first anniversary of the grant date or the Issuer's next annual meeting of shareholders, contingent upon continued service as a director.
- The options expire on June 25, 2034.
- Following the transaction, Goyal beneficially owns 48,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. Insider ownership is generally viewed favorably, but this is a standard transaction.
Positives
- The acquisition of share options by a director signals confidence in the company's future performance.
Future Outlook
The vesting of the options is contingent upon continued service as a director, aligning Goyal's interests with the company's long-term success.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of share options by a director can positively influence shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 06/25/2024 | Date of transaction: Arjun Goyal acquired share options. |
| 06/25/2024 | Grant date of the share options. |
| 06/25/2034 | Expiration date of the share options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.